Estimates Revisions Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
After hours 07:12:40 pm | |||
| 218.70 USD | -0.32% |
|
225.79 | +3.24% |
| Jul. 20 | Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… |  |
| Jul. 13 | BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- CRL Stock
- Consensus Charles River Laboratories International, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
